WAVEMAN · COMPANY

ALNY · Alnylam Pharmaceuticals, Inc.

LIVE

TEAM-0.32% 13F +439META+2.47% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV-1.12% 13F +693CRM-0.46% 13F +1,018CVNA+2.74% 13F +794TPL-0.71% 13F +444NET-4.47% 13F +710MSTR-1.35% 13F +526DELL+15.81% 13F +1,203CRWD-5.42% 13F +1,382ANET+2.87% 13F +1,323COIN-1.05% 13F +475TEAM-0.32% 13F +439META+2.47% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV-1.12% 13F +693CRM-0.46% 13F +1,018CVNA+2.74% 13F +794TPL-0.71% 13F +444NET-4.47% 13F +710MSTR-1.35% 13F +526DELL+15.81% 13F +1,203CRWD-5.42% 13F +1,382ANET+2.87% 13F +1,323COIN-1.05% 13F +475

← ALL COMPANIES

ALNY

Name: ALNYLAM PHARMACEUTICALS, INC. (ALNY) insider trading and ownership data
Creator: WaveMan
License: https://wave-man.com/terms

ALNYLAM PHARMACEUTICALS, INC.

PHARMA & BIOTECH · PHARMACEUTICAL PREPARATIONS · CIK 0001178670

SEC FILINGS☆ WATCH

INSIDER NET · 180D

-$2.4M

open-market buys minus sells, Form 4 codes P and S

INSIDER BUYERS · 180D

CONGRESS BUYERS · 1Y

FUNDS ADDED · QTR

413

13F, latest reported quarter

REVENUE GROWTH

+65.2%

XBRL, annual

NET MARGIN

8.4%

CONVERSIONS · 180D

codes C/M, not in net · $789.8K priced

SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST

INSIDERS

net -$2.4M over 180 days

below 71% of Pharma & Biotech

CONGRESS

no member of Congress has reported trading it

FUNDS

413 funds added or opened last quarter

more than 95% of Pharma & Biotech

REVENUE

+65.2% year over year

more than 82% of Pharma & Biotech

MARGIN

8.4% net margin

more than 78% of Pharma & Biotech

BUYBACKS

no share repurchases reported

SHORT

3.6% of shares outstanding short · 2.2 days to cover · settled 2026-07-31

below 54% of Pharma & Biotech

THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET

413 funds added or opened positions in the latest 13F quarter, of 794 holders.

The year, with the filings on it

Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail

TOTAL 12M RETURN -40.8%

-40.8%12M

INSIDER SELL

INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY

Live price

Daily candles from TradingView, on their licence — no filings are marked on this one

WHY THIS NAME IS ON THE DESK

The complete filing record, in one place.

The record shows a net $2.4M sold by insiders over 180 days, 413 funds added last quarter. Every figure is a federal filing, dated the day it became public.

Backtest this pattern Open the screener

Same sector, ranked by filing activity

Sector from the SEC's own SIC classification

UTHR CPIX MRNA REGN LLY ELF CITR MDGL DNA VRTX NUVL INSM

Insider transactions

Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, ALNYLAM PHARMACEUTICALS, INC. insiders sold a net $2.4M of stock across 906 Form 4 purchases and sales, with 0 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-04.

INSIDER

FILED

VALUE

PYOTT DAVID E I

Director

SELL

2026-06-01

1,175.0

$351.2K

PYOTT DAVID E I

Director

SELL

2026-06-01

17.0

$5.1K

PYOTT DAVID E I

Director

SELL

2026-06-01

921.0

$274.2K

PYOTT DAVID E I

Director

SELL

2026-06-01

495.0

$148.9K

PYOTT DAVID E I

Director

SELL

2026-06-01

1,222.0

$366.4K

906 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 901 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders

13F · holdings as of the latest quarter funds have reported

FMR LLC

15,023,962.0 sh

$4.5B

Capital World Investors

11,144,846.0 sh

$3.4B

BlackRock, Inc.

10,907,675.0 sh

$3.3B

Capital Research Global Investors

9,750,699.0 sh

$2.9B

VANGUARD PORTFOLIO MANAGEMENT LLC

6,538,390.0 sh

$2.0B

SCHEDULE 13D/G

No 5%+ ownership filings

Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.

FORM 144

No planned-sale notices

No insider has notified an intent to sell. This is the panel to watch after a run-up.

Fund concentration

N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show

Fidelity Advisor Biotechnology Fund

$105.1M POSITION · AS OF 2026-04-30

5.5%

Invesco Biotechnology & Genome ETF

$12.0M POSITION · AS OF 2026-04-30

4.8%

Nestyield Dynamic Income ETF

$3.9M POSITION · AS OF 2026-02-28

4.7%

NestYield Visionary ETF

$2.8M POSITION · AS OF 2026-02-28

4.6%

Horizon Kinetics Medical ETF

$751.7K POSITION · AS OF 2026-03-31

4.1%

VanEck Biotech ETF

$15.3M POSITION · AS OF 2026-03-31

4.1%

SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK

Clinical pipeline

ClinicalTrials.gov · 56 registered trials, 26 still enrolling or running — a status change here is dated weeks before the press release

Phase 1

7 ACTIVE

Phase 2

5 ACTIVE

Phase 3

5 ACTIVE

Not applicable

6 ACTIVE

Multi-phase

3 ACTIVE

What changed recently

A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy

2026-09-04 · Recruiting → Active Not Recruiting

Phase 2

TRIALS MATCHED TO THIS TICKER BY SPONSOR NAME · STUDIES RUN UNDER A SUBSIDIARY'S OWN NAME ARE NOT INCLUDED

Corporate PAC

FEC · the company-connected political action committee's own receipts and spending — committee totals only, never individual donors

Alnylam Pharmaceuticals, Inc. Political Action Committee (Alnylam Pac)

CYCLE 2026 · $178K SPENT

$149.7K

FEDERAL ELECTION COMMISSION · MATCHED BY THE PAC'S CONNECTED ORGANISATION

Executive pay vs shareholder return · Yvonne L. Greenstreet, M.D.

DEF 14A pay-versus-performance disclosure · both the headline pay and the SEC's mark-to-market figure, beside the return the company delivered and the return of the peer group it chose itself

CEO TOTAL

ACTUALLY PAID

OTHER NEOs AVG

TSR

PEER TSR

2025

$14.9M

$77.4M

$6.6M

+206%

+25%

2024

$11.5M

$29.8M

$3.0M

+81%

-7%

2023

$8.9M

$11.4M

$2.9M

+47%

-6%

2022

$4.6M

$19.0M

$3.6M

+83%

-10%

2021

$10.2M

$17.5M

$5.9M

+30%

+0%

TAGGED BY THE COMPANY UNDER SEC ITEM 402(v) · RETURN IS CUMULATIVE FROM THE START OF THE DISCLOSURE PERIOD · GREEN WHERE THE COMPANY BEAT ITS OWN PEER GROUP

Fundamentals

Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all

	2025-12	2024-12	2023-12	2022-12
REVENUE	$3.7B	$2.2B	$1.8B	$1.0B
OPERATING INCOME	$501.6M	$-176.9M	$-282.2M	$-785.1M
NET INCOME	$313.7M	$-278.2M	$-440.2M	$-1.1B
EPS (DILUTED)	2.33	-2.18	-3.52	-9.30
OPERATING CASH FLOW	$524.1M	$-8.3M	$104.2M	$-541.3M
CASH	$1.7B	$966.4M	$812.7M	$866.4M

SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-04 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE